Will These Numbers from Nxstage Medical Be Good Enough for You?
Nxstage Medical (NAS: NXTM) is expected to report Q1 earnings on May 2. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Nxstage Medical's revenues will grow 7.3% and EPS will remain in the red.
The average estimate for revenue is $61.1 million. On the bottom line, the average EPS estimate is -$0.08.
Last quarter, Nxstage Medical tallied revenue of $65.0 million. GAAP reported sales were 14% higher than the prior-year quarter's $57.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.04. GAAP EPS were -$0.04 for Q4 versus -$0.08 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 39.0%, 190 basis points better than the prior-year quarter. Operating margin was -2.9%, 270 basis points better than the prior-year quarter. Net margin was -3.6%, 440 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $264.5 million. The average EPS estimate is -$0.24.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 139 members out of 170 rating the stock outperform, and 31 members rating it underperform. Among 46 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 38 give Nxstage Medical a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nxstage Medical is outperform, with an average price target of $17.00.
Is Nxstage Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Nxstage Medical to My Watchlist.
The article Will These Numbers from Nxstage Medical Be Good Enough for You? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool recommends NxStage Medical. The Motley Fool owns shares of NxStage Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.